Brainomix Wins Two Awards for AI Imaging Technology

Brainomix has been named the LSX European Lifestars “Healthtech Company of the Year” and the OBN “Most Transformative Healthtech Company of the Year.” These awards highlight the company’s advancements in stroke and lung fibrosis imaging, its expansion into the U.S. market, and its measurable impact on patient care.

Founded in 2010 as a spin-out from the University of Oxford’s Nuffield Department of Clinical Neurosciences, Brainomix specializes in AI-powered imaging solutions for stroke, lung disease, and cancer. Co-founded by Dr. Michalis Papadakis, the company operates in over 30 countries, delivering clinically adopted tools to hundreds of hospitals worldwide.

Judges cited the company’s achievements, including National Institute for Health & Care Excellence (NICE) endorsements, multiple FDA clearances, and real-world evidence showing improved treatment rates. In Hungary, Brainomix 360 Stroke has increased thrombectomy rates by over 50%, while Wales reported a 44% increase.

Dr. Michalis Papadakis, CEO, said:

“These awards reflect the measurable impact our technology is having on patient care, and we remain focused on delivering solutions that improve outcomes for stroke and lung fibrosis patients worldwide.”

e-ASPECTS showcased here as a phone app, is a part of the Brainomix 360 Stroke platform, detects and measures stroke markers, providing automated ASPECTS scoring and overlaid heatmaps to aid clinicians in decision-making.

Brainomix’s flagship 360 platform applies AI to improve diagnostic accuracy and treatment decisions across multiple diseases:

• Stroke Imaging:
  The Brainomix 360 Stroke platform includes FDA-cleared tools that analyze brain scans in real time, guiding clinicians on treatment decisions, including thrombectomy eligibility. Studies have shown it increased the rate of patients achieving functional independence post-stroke from 16% to 48% at one center and reduced door-in-door-out (DIDO) times by 61 minutes.
  
  Solutions across the full stroke pathway include e-ASPECTS for detecting and measuring stroke markers, e-CTA for collateral and LVO assessments, e-CTP for perfusion analysis, a Trials Tracker for streamlining clinical trial inclusion and management, and other tools.

• Lung Disease:
  The e-Lung solution provides imaging biomarkers to assess interstitial lung disease (ILD) progression and improve patient selection for clinical trials. The tools predict outcomes more effectively than current standards like Forced Vital Capacity (FVC), aiding early diagnosis and treatment.

• Cancer:
  Brainomix’s oncology tools quantify solid tumors and assess treatment efficacy in clinical trials. They support early-stage assessments and aim to reduce trial timelines.

Topics: HealthTech